Clinical Trial Update: Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing lapatinib plus capecitabine to trastuzumab plus capecitabine in HER2-positive metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Metastases, Brain | Phase 3 | Status: COMPLETED | Results posted: 2013-03-15